Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372507 | 1.00 | MERTK (0.39) | MERTKCDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL4372753 | 0.87 | CDK2 (0.49) | CDK2CCNA2CDK5CDK5R1JAK1 | |
| SCHEMBL4372748 | 0.87 | CDK2 (0.49) | CDK2CCNA2CDK5CDK5R1JAK1 | |
| SCHEMBL4374864 | 0.84 | FLT3 (0.43) | MERTKCDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL4374861 | 0.84 | FLT3 (0.43) | MERTKCDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL6753756 | 0.83 | KMT2A (0.35) | CDK2CCNA2CDK5CDK5R1JAK1 | |
| SCHEMBL4372906 | 0.82 | CDK2 (0.54) | CDK2CCNA2CDK5CDK5R1FLT3 | |
| SCHEMBL4372901 | 0.82 | CDK2 (0.54) | CDK2CCNA2CDK5CDK5R1FLT3 | |
| SCHEMBL4372328 | 0.71 | FLT3 (0.55) | MERTKCDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL4372495 | 0.71 | FLT3 (0.55) | MERTKCDK2CCNA2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7429595-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-6861524-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040248908-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1377579-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Aventis Pharmaceuticals Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTISUB LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | BAD, BAX, MCL1 | MERTK 3594/4885CDK2 167/4885CCNA2 233/4885 |
| US-20040248908-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | TYMP, TK1, SLC29A1 | MERTK 3575/4885CDK2 68/4885CCNA2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.